Alex Bataller: Phase 1/2 trial results of oral decitabine/cedazuridine with venetoclax in higher risk MDS and CMML

Alex Bataller, Leukemia fellow at Leukemia Department, MD Anderson Cancer Center (Houston, Texas), shared a post on X/Twitter:

”Delighted to announce our newest publication in The Lancet Haematology of the phase 1/2 trial results of oral decitabine/cedazuridine with venetoclax in higher risk MDS and CMML.

This totally oral combination had an acceptable toxicity profile with an encouraging ORR of 95% and 49% of patients undergoing subsequent HSCT.”

Source: Alex Bataller/X